These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28398628)

  • 1. Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.
    Muralidharan KK; Kuesters G; Plavina T; Subramanyam M; Mikol DD; Gopal S; Nestorov I
    J Clin Pharmacol; 2017 Aug; 57(8):1017-1030. PubMed ID: 28398628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter GR; Giovannoni G; Killestein J; Wiendl H; Li K; Dsilva L; Toukam M; Ferber K; Sohn J; Engelman H; Lasky T
    Neurol Neuroimmunol Neuroinflamm; 2024 Dec; 11(6):e200321. PubMed ID: 39393045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
    Plavina T; Fox EJ; Lucas N; Muralidharan KK; Mikol D
    J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
    Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR
    Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.
    Muralidharan KK; Steiner D; Amarante D; Ho PR; Mikol D; Elkins J; Subramanyam M; Nestorov I
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):263-275. PubMed ID: 28251386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.
    Ghezzi A; Comi G; Grimaldi LM; Moiola L; Pozzilli C; Fantaccini S; Gallo P
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep; 6(5):e591. PubMed ID: 31355324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
    Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M;
    Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing.
    Chang I; Muralidharan KK; Campbell N; Ho PR
    J Clin Pharmacol; 2021 Mar; 61(3):339-348. PubMed ID: 32949472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.
    Dallari S; Franciotta D; Carluccio S; Signorini L; Gastaldi M; Colombo E; Bergamaschi R; Elia F; Villani S; Ferrante P; Delbue S
    J Neuroimmunol; 2015 Oct; 287():76-9. PubMed ID: 26439965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody.
    Li H; Shi FH; Huang SY; Zhang SG; Chen ML
    Curr Drug Metab; 2018; 19(14):1213-1223. PubMed ID: 29708072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Plavina T; Muralidharan KK; Kuesters G; Mikol D; Evans K; Subramanyam M; Nestorov I; Chen Y; Dong Q; Ho PR; Amarante D; Adams A; De Sèze J; Fox R; Gold R; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Hartung HP; Cree BAC
    Neurology; 2017 Oct; 89(15):1584-1593. PubMed ID: 28916537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy.
    Bringeland GH; Blaser N; Myhr KM; Vedeler CA; Gavasso S
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32019768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis.
    Proschmann U; Inojosa H; Akgün K; Ziemssen T
    Front Neurol; 2021; 12():650530. PubMed ID: 33935948
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacodynamics of natalizumab extended interval dosing in MS.
    Zhovtis Ryerson L; Li X; Goldberg JD; Hoyt T; Christensen A; Metzger RR; Kister I; Foley J
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 32019876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natalizumab wearing-off effect: End of natalizumab cycle, recurrence of MS symptoms.
    van Kempen ZLE; Doesburg D; Dekker I; Lissenberg-Witte BI; de Vries A; Claessen IA; Brinke AT; Rispens T; Killestein J
    Neurology; 2019 Oct; 93(17):e1579-e1586. PubMed ID: 31551258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab treatment of multiple sclerosis: new insights.
    Delbue S; Comar M; Ferrante P
    Immunotherapy; 2017 Jan; 9(2):157-171. PubMed ID: 28004598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA; Sandrock A
    Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.
    Vollmer TL; Phillips JT; Goodman AD; Agius MA; Libonati MA; Giacchino JL; Grundy JS
    Mult Scler; 2004 Oct; 10(5):511-20. PubMed ID: 15471366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of natalizumab in the treatment of multiple sclerosis.
    Coyle PK
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S164-70. PubMed ID: 20615052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.